Antipsychotic Maintenance Treatment: Time to Rethink?
- PMID: 26241954
- PMCID: PMC4524699
- DOI: 10.1371/journal.pmed.1001861
Antipsychotic Maintenance Treatment: Time to Rethink?
Abstract
Joanna Moncrieff looks at the lack of long-term evidence for antipsychotic medication and considers what is needed to ensure we have the knowledge to maximize benefits and minimize harms.
Conflict of interest statement
I have read the journal's policy and have the following conflicts: I am a member and co-chairman of the Critical Psychiatry Network (
References
-
- Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005. August;15(4):399–409. - PubMed
-
- Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005. September;66(9):1122–9. - PubMed
-
- Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, an der HW, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med 2000. September;30(5):1155–67. - PubMed
-
- CRANE GE. Clinical psychopharmacology in its 20th year. Late, unanticipated effects of neuroleptics may limit their use in psychiatry. Science 1973. July 13;181(4095):124–8. - PubMed
-
- Royal College of Psychiatrists. Report of the Second Round of the National Audit of Schizophrenia (NAS) 2014. London: Healthcare Quality Improvement Partnership; 2014.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
